Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precision Biosciences Inc

5.33
-0.1700-3.09%
Volume:69.47K
Turnover:373.55K
Market Cap:55.87M
PE:5.13
High:5.68
Open:5.49
Low:5.16
Close:5.50
Loading ...

Top Midday Gainers

MT Newswires Live
·
11 Jan

BMO Capital Upgrades Precision BioSciences to Outperform From Market Perform, Price Target is $34

MT Newswires Live
·
10 Jan

Top Premarket Gainers

MT Newswires Live
·
10 Jan

Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan

Precision BioSciences Inc : Bmo Raises to Outperform From Market Perform

THOMSON REUTERS
·
10 Jan

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner Iecure in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (Otc) Deficiency

THOMSON REUTERS
·
09 Jan

Precision BioSciences Inc - Ecur-506 Generally Well Tolerated With No Significant Safety Concerns

THOMSON REUTERS
·
09 Jan

Iecure Reports Complete Clinical Response in First Infant Dosed With Its in Vivo Gene Editing Candidate Ecur-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (Otc) Deficiency

THOMSON REUTERS
·
09 Jan

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Business Wire
·
09 Jan

BRIEF-Precision Biosciences Expects Cash Runway Into H2 2026

Reuters
·
08 Jan

Precision BioSciences Inc - Expects Cash Runway Into Second Half of 2026

THOMSON REUTERS
·
08 Jan

BRIEF-Precision Biosciences Receives Approval In Hong Kong To Expand Pbgene-Hbv Phase 1 Eliminate-B Trial

Reuters
·
18 Dec 2024

Precision BioSciences Receives Approval in Hong Kong to Expand Pbgene-Hbv Phase 1 Eliminate-B Trial for the Treatment of Chronic Hepatitis B

THOMSON REUTERS
·
18 Dec 2024

Precision BioSciences Inc - U.S. Ind for Pbgene-Hbv Anticipated in 2025

THOMSON REUTERS
·
18 Dec 2024

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Business Wire
·
18 Dec 2024

Precision BioSciences to Participate in Upcoming November Investor Conferences

Business Wire
·
21 Nov 2024

Precision BioSciences to present preclinical PBGENE-HBV data

TIPRANKS
·
15 Nov 2024

BRIEF-Precision Biosciences Highlights Preclinical Data, Outlines Design Of First-In-Human Clinical Trial For PBGENE-HBV

Reuters
·
15 Nov 2024

Precision BioSciences Inc - Phase 1 Trial Eliminate-B to Assess Safety and Efficacy

THOMSON REUTERS
·
15 Nov 2024

Precision BioSciences Inc - Global Study Recruiting Patients, U.S. Ind Expected in 2025

THOMSON REUTERS
·
15 Nov 2024